Global healthcare company Novo Nordisk has announced that it has opened a regional office in Nairobi to serve as the headquarters of its operations in Sub-Saharan Africa.

Novo Nordisk is a global healthcare company headquartered in Denmark with more than 95 years of innovation and leadership in diabetes care. The company supplies nearly half of the world’s insulin.

Some of the key projects that the company has undertaken in Kenya include the Base of the Pyramid (BoP) project that works to improve access to diabetes care for people at the base of the economic pyramid. It also includes the Changing Diabetes in Children (CDiC) programme that aims to bring all elements of necessary diabetes care closer to the children and build capacity for the diagnosis and treatment of children with type 1 diabetes living in resource-poor settings. These projects are also being implemented in other countries in the region.

These initiatives focus on educating patients, supporting decision makers, training healthcare professionals, and strengthening healthcare systems. The partnerships include the Ministries of Health, Diagnostic Companies, Faith-based Organisatons, NGOs, Drug Supply Organizations, Healthcare Professionals, Patient Associations and the Royal Danish embassy. The projects identify solutions help in adopting an integrated approach to diagnosis, treatment and diabetes control. The ultimate aim is that more people with diabetes live better lives.

Novo Nordisk formed the Middle Africa affiliate in 2012 comprising 49 countries across sub-Saharan Africa with Headquarters located in Dubai, UAE. This is where the management team was based and carried out operations. On 1st July 2018, the affiliate headquarters was relocated from Dubai, UAE to Nairobi, Kenya in order to drive business growth by being closer to the markets.

Novo Nordisk is a global healthcare company with more than 95 years of experience in diabetes care. This has helped people combat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries, and markets its products in more than 170 countries.